$0.17
+0.01 (+7.49%)
Open$0.17
Previous Close$0.15
Day High$0.17
Day Low$0.15
52W High$0.77
52W Low$0.03
Volume—
Avg Volume4.36M
Market Cap30.33M
P/E Ratio—
EPS$-0.38
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+12,197.0% upside
Current
$0.17
$0.17
Target
$20.29
$20.29
$11.90
$20.29 avg
$29.33
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 27.90M | 39.38M | 23.70M |
| Net Income | -86,670,952 | -110,128,274 | -3,056,252 |
| Profit Margin | -310.8% | -295.3% | -12.9% |
| EBITDA | -82,699,933 | -110,920,424 | -4,785,189 |
| Free Cash Flow | — | — | -2,136,953 |
| Rev Growth | -29.2% | -29.2% | +16.7% |
| Debt/Equity | — | — | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $258.92 | +3.43% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $425.28 | +1.41% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $143.44 | +3.25% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $528.19 | +2.45% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $810.24 | +0.53% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.61 | +1.79% | 37.6 | 30.39B |